GATC Health Enters Clinical Development of Breakthrough Compounds for the Treatment of Fentanyl Addiction and Opioid Use Disorders
The drug’s mechanism is potentially the first to rewire and restore the brain, addressing a root cause of opioid addiction and may have application for treating other neurological diseases
IRVINE, Calif., October 6, 2022 /PRNewswire/ — GATC Health (“GATC” or “the Company”), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), announced today Today, the new drug candidates discovered by its proprietary AI and prediction platform to treat opioid use disorder (OUD) and fentanyl addiction have entered preclinical development. GATC partners with Christie D. Fowlerdoctorate at the University of California, Irvine (UCI) and world leader in scientific testing, Eurofins Discovery, for preclinical programs to determine the safety and efficacy of new drug candidates in reducing opioid use, withdrawal symptoms and relapses.
To uncover these specific drug candidates for OUD, GATC obtained drug target biomarkers for drug addiction from Liquid Biosciences, a leading company in AI-based biomarker discovery, and created a detailed disease model. with its proprietary Multiomics Advanced Technology™ (MAT) platform. The platform then assembled and analyzed thousands of potential drug compounds, ultimately delivering a small set of high-quality new drug candidates that could directly affect the root causes of addiction.
These drug candidates are designed to support the brain’s ability to change and adapt in response to experience, by restoring natural dopamine levels and reducing brain inflammation. The effects of this type of treatment have the potential to be safer for the patient and could provide a significant benefit in short and long term recovery.
GATC recently published a study showing that its platform can successfully predict drug success with an accuracy of 88% and, importantly, predict drug failure with an unprecedented accuracy rate of 84%. %. With vast improvements in speed and accuracy, GATC has proven an 11x increase over the current industry lead optimization success rate of around 8%.
“We deliberately directed our AI drug discovery and prediction platform to pursue the discovery of potential treatments for fentanyl addiction and opioid use disorders, incredibly difficult to treat diseases. an area of enormous unmet patient need that has laws, policies and tens of billions of dollars in financial support,” said Jeff Moses, Chairman of GATC Health. “Our platform, in just a few short months, has potentially discovered the missing link in treatments for neurological diseases – a groundbreaking discovery that has incredible implications for the opioid epidemic and other fields of medicine.”
Through the platform’s new drug discovery, GATC has the potential to improve other treatments such as drug addiction, post-traumatic stress disorder (PTSD), Alzheimer’s disease, Parkinson’s disease, major depressive disorder (MDD) and other neurological diseases.
GATC Health’s advanced AI platform reduces the risk, time and cost of developing more effective drugs and treatments. GATC can analyze massive amounts of disease-specific data, with an AI solution that understands the basic biology of a disease and can mimic a human environment for new drug discovery and validation. The Company’s MAT platform can analyze 400 trillion biological data points in seven minutes and simulate biochemical interactions to accurately predict a pharmaceutical active’s response to a specific disease. The MAT platform can develop 1-3 new drug candidates in 3-6 months with the ability to support end-to-end services in research and development.
“GATC’s drug candidates for the treatment of fentanyl and opioid addiction focus on gently stimulating the rewiring of emotional reward circuitry in the brain, without causing the sharp fluctuations in neurohormone levels that typically lead to addiction,” said dr. Robert Sorrentin, Chief Medical Officer of GATC Health. “Essentially, the compounds remove barriers to recovery and send a signal telling the patient’s body to begin its recovery process and return to a balanced state.”
The opioid epidemic is one of the leading causes of death in the United States and one of the main factors in the country’s declining life expectancy rate, with more than 150 Americans dying every day. synthetic opioid overdoses.1, 2 Drug-related overdose deaths have also risen dramatically in recent years, rising by 30% from 70,630 before the COVID-19 pandemic in 2019 to 91,799 deaths in 2020.3
Recent deals with opioid manufacturers have generated tens of billions of dollars in funding for opioid reduction, in addition to federal and state grants to address the opioid epidemic.4, 5 High priority in the United States, the Biden administration has asked Congress $42.5 billion for drug control programs.6
About GATC Health
GATC Health Corp is a pioneering technology company that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and cost for life science companies by digitally replicating the human body to find non-obvious answers to the most complex questions in biology. GATC Health accelerates the transition of health care towards predictive and individualized medicine.
The information contained herein is presented for informational purposes only and should not be considered an offer to sell securities. This announcement contains information that the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee the accuracy or completeness of this information. The Company reserves the right to modify or amend the information contained in this document.
SOURCE GATC Health